SCHEMBL2758655

SCHEMBL2758655

CC(C)NC(=O)C1CCN(C(C)C)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
MEN1 O00255 1/20 0.62
HRH3 Q9Y5N1 2/20 0.49
CYP2D6 P10635 1/20 0.49
TSHR P16473 1/20 0.49
POLB P06746 2/20 0.48
GAA P10253 1/20 0.44
LMNA P02545 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA7 P36544 1/20 0.43
CHRNA4 P43681 1/20 0.43
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18705030 0.89 MEN1 (0.54) KMT2ASMN1; SMN2MEN1HRH3CYP2D6
SCHEMBL12026414 0.82 HRH3 (0.46) KMT2ASMN1; SMN2MEN1HRH3CYP2D6
SCHEMBL12197840 0.82 KMT2A (0.64) KMT2ASMN1; SMN2MEN1TSHRPOLB
SCHEMBL19605448 0.82 HDAC8 (0.48) KMT2ASMN1; SMN2MEN1HRH3CYP2D6
SCHEMBL18712995 0.81 SMN1; SMN2 (0.43) KMT2ASMN1; SMN2MEN1HRH3CYP2D6
SCHEMBL172134 0.81
SCHEMBL10076786 0.81 SMN1; SMN2 (0.60) KMT2ASMN1; SMN2MEN1TSHRPOLB
SCHEMBL1119521 0.81 HRH3 (0.45) KMT2ASMN1; SMN2MEN1HRH3CYP2D6
SCHEMBL17789624 0.80 HRH3 (0.49) KMT2ASMN1; SMN2MEN1HRH3CYP2D6
SCHEMBL20315439 0.80 TSHR (0.60) KMT2ASMN1; SMN2MEN1HRH3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 US disclosed
US-20230227826-A1 UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES ARCTURUS THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230227826-A1 UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES ARCTURUS THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20210060168-A1 ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES ARCTURUS THERAPEUTICS, INC. 2021-03-04 US disclosed
US-20190127373-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2019-05-02 US disclosed
US-10174027-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-20180186791-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-9877957-B2 Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 MERCK SHARP & DOHME CORP. (US) 2018-01-30 US disclosed
US-8748412-B2 Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators ARGUSINA BIOSCIENCE INC. (KY) 2014-06-10 US disclosed
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227826-A1 UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES HNRNPR, HNRNPK, ATXN2 KMT2A 2755/4885SMN1; SMN2 280/4885MEN1 3064/4885
US-20190127373-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF KMT2A 1448/4885SMN1; SMN2 989/4885MEN1 1015/4885
US-10174027-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF KMT2A 1448/4885SMN1; SMN2 989/4885MEN1 1015/4885
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, GPR119 KMT2A 2731/4885SMN1; SMN2 3331/4885MEN1 1612/4885
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF KMT2A 1448/4885SMN1; SMN2 989/4885MEN1 1015/4885
US-20180186791-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF KMT2A 1448/4885SMN1; SMN2 989/4885MEN1 1015/4885
US-20240024488-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KMT2A 792/4885SMN1; SMN2 40/4885MEN1 1366/4885
US-20210060168-A1 ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES ASGR1, FCGR2A, FCGR3B KMT2A 4273/4885SMN1; SMN2 3266/4885MEN1 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.